TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
GH Research ( (GHRS) ) just unveiled an announcement.
GH Research PLC announced its participation in the upcoming Cantor Global Healthcare Conference in New York from September 3-5, 2025. The company aims to engage with investors through a fireside chat and one-on-one meetings, which could enhance its visibility and investor relations in the healthcare sector.
The most recent analyst rating on (GHRS) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
GH Research’s stock score reflects significant challenges in financial performance, with consistent losses and negative cash flows. The company’s strong equity base and low debt provide some stability. Technical indicators show some short-term momentum, but valuation concerns persist due to the negative P/E ratio and lack of profitability.
To see Spark’s full report on GHRS stock, click here.
More about GH Research
GH Research PLC operates in the healthcare industry, focusing on innovative medical research and development. The company is known for its work in advancing healthcare solutions and engaging with investors to further its market presence.
Average Trading Volume: 269,465
Technical Sentiment Signal: Buy
Current Market Cap: $858.5M
For detailed information about GHRS stock, go to TipRanks’ Stock Analysis page.